These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16141258)

  • 21. Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy.
    Bell SP; Adkisson DW; Lawson MA; Wang L; Ooi H; Sawyer DB; Kronenberg MW
    J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25164945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy].
    Skvortsov AA; Mareev VIu; Orlova IaA; Chelmakina SM; Baklanova NA; Belenkov IuN
    Kardiologiia; 2008; 48(2):52-64. PubMed ID: 18261010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction.
    Lax A; Sanchez-Mas J; Asensio-Lopez MC; Fernandez-Del Palacio MJ; Caballero L; Garrido IP; Pastor-Perez FJ; Januzzi JL; Pascual-Figal DA
    JACC Heart Fail; 2015 Jan; 3(1):50-58. PubMed ID: 25458175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy.
    Wahed MI; Watanabe K; Ma M; Yamaguchi K; Takahashi T; Tachikawa H; Kodama M; Aizawa Y
    Pharmacology; 2005 Feb; 73(2):81-8. PubMed ID: 15467302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing.
    Zhao J; Li J; Li W; Li Y; Shan H; Gong Y; Yang B
    Br J Pharmacol; 2010 Apr; 159(8):1584-94. PubMed ID: 20082611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy.
    Maron MS; Chan RH; Kapur NK; Jaffe IZ; McGraw AP; Kerur R; Maron BJ; Udelson JE
    Am J Med; 2018 Jul; 131(7):837-841. PubMed ID: 29604289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure.
    Nehme JA; Lacolley P; Labat C; Challande P; Robidel E; Perret C; Leenhardt A; Safar ME; Delcayre C; Milliez P
    J Mol Cell Cardiol; 2005 Sep; 39(3):511-9. PubMed ID: 15992819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy].
    Skvortsov AA; Mareev VY; Chelmakina SM; Baklanova NA; Belenkov IuN
    Kardiologiia; 2007; 47(10):12-23. PubMed ID: 18260939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction].
    Tsutamoto T
    Nihon Yakurigaku Zasshi; 2004 Aug; 124(2):90-100. PubMed ID: 15277727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of combined spironolactone-β-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study).
    Dabrowski R; Borowiec A; Smolis-Bak E; Kowalik I; Sosnowski C; Kraska A; Kazimierska B; Wozniak J; Zareba W; Szwed H
    Am J Cardiol; 2010 Dec; 106(11):1609-14. PubMed ID: 21094362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A beneficial effect of 3-year spironolactone therapy supplementing atenolol therapy on the remodeling of atria and ventricles in a patient with permanent atrial fibrillation.
    Dabrowski R; Sosnowski C; Michalak E; Szwed H
    Intern Emerg Med; 2009 Apr; 4(2):171-3. PubMed ID: 19225860
    [No Abstract]   [Full Text] [Related]  

  • 32. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
    Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
    JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats.
    Cezar MD; Damatto RL; Pagan LU; Lima AR; Martinez PF; Bonomo C; Rosa CM; Campos DH; Cicogna AC; Gomes MJ; Oliveira SA; Blotta DA; Okoshi MP; Okoshi K
    Cell Physiol Biochem; 2015; 36(4):1453-66. PubMed ID: 26160286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction.
    Schäfer A; Fraccarollo D; Hildemann SK; Tas P; Ertl G; Bauersachs J
    Cardiovasc Res; 2003 Jun; 58(3):655-62. PubMed ID: 12798439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction].
    Yoshiyama M; Omura T; Yoshikawa J
    Nihon Yakurigaku Zasshi; 2004 Aug; 124(2):83-9. PubMed ID: 15277726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial.
    Shantsila E; Haynes R; Calvert M; Fisher J; Kirchhof P; Gill PS; Lip GY
    BMJ Open; 2016 Oct; 6(10):e012241. PubMed ID: 27707827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Suzuki G; Morita H; Mishima T; Sharov VG; Todor A; Tanhehco EJ; Rudolph AE; McMahon EG; Goldstein S; Sabbah HN
    Circulation; 2002 Dec; 106(23):2967-72. PubMed ID: 12460880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High prevalence of atrial fibrosis in patients with dilated cardiomyopathy.
    Ohtani K; Yutani C; Nagata S; Koretsune Y; Hori M; Kamada T
    J Am Coll Cardiol; 1995 Apr; 25(5):1162-9. PubMed ID: 7897130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation.
    Pellman J; Lyon RC; Sheikh F
    J Mol Cell Cardiol; 2010 Mar; 48(3):461-7. PubMed ID: 19751740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.